This year at the AMP Annual Meeting, we appreciated the opportunity to reconnect with familiar faces, meet new colleagues, and hear how labs and teams are tackling real-world challenges in molecular diagnostics.
Our team spent the week meeting with molecular pathologists, geneticists, and pharma partners, leading a workshop on literature-derived real-world evidence (RWE), and giving live demos of our platforms - the Cancer Knowledgebase (CKB) and the Mastermind Genomic Intelligence Platform- right at the booth.
During AMP, we hosted a workshop titled: “Revealing the Value of Literature-Based Real-World Evidence: Transforming Trial Design, Label Expansion, and Clinical Decision-Making”
Real-world evidence from published clinical literature offers a powerful - yet still underused - lens into patient outcomes, therapeutic response, and biomarker discovery. In the workshop, we walked through how literature-derived RWE augments traditional real-world data sources (like EHRs and registries) by uncovering:
- Patient-level insights (phenotypes, comorbidities, treatment history)
- Variant-level details (pathogenicity, functional evidence, co-occurring variants)
- Therapy response patterns that are often buried in thousands of publications
We showed how this evidence can be used to:
- Optimize trial design and eligibility criteria
- Support label expansion in rare or complex indications
- Refine clinical decision-making in precision oncology
From there, we showed how CKB turns this curated evidence into structured, queryable insights: efficacy data, guidelines, clinical trials, and variant-specific evidence that directly supports therapeutic decision-making.
Live Demos at the Booth: From Concept to Click
Our engagement continued beyond the workshop, with live demonstrations of the Cancer Knowledgebase and Mastermind.
Attendees had the opportunity to sit down with the Genomenon team, investigate specific genes or variants and see firsthand how curated literature-derived RWE transforms the interpretation process. It shifts the conversation from simply asking - “can we find any evidence” to a more proactive, “how much evidence do we have and what are its clinical implications”.
What We Heard from AMP Attendees
Across conversations at the booth and in sessions, a few themes came up again and again:
- Timely insights. As the pace of new evidence accelerates, staying current is harder than ever. Genomenon delivers continuously updated, structured insights that help teams keep up with new discoveries while reducing the burden of manual review.
- Broader coverage. Panels are getting bigger - and so is the evidence behind them. Genomenon provides a comprehensive, scalable content foundation that supports today’s assays and grows with them as they evolve.
Couldn’t Make it to AMP? Let’s connect!
If you weren’t able to join us at AMP - or if you saw the workshop and want to go deeper - we’d love to continue the conversation. Here are a few ways to follow up:Request a demo of CKB or Mastermind tailored to your lab, program, or indication
- Request a demo of CKB or Mastermind tailored to your lab, program, or indication
- Explore literature-derived RWE use cases for your oncology or rare disease pipelines
- Discuss specific trial or label-expansion questions where curated literature evidence could fill critical gaps
Contact our team if you’d like to continue the conversation - we’re glad to explore how literature-derived RWE can support your next project, from variant interpretation to trial design and beyond.
